Verition Fund Management’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
BBA
Verition Fund Management's NRIX Position: Q3 2026 in Review
Verition Fund Management sold out of Nurix Therapeutics (NRIX) in Q3 2026, closing a stake of 30,405 shares — an estimated $738K sold.
Verition Fund Management first reported a position in NRIX in Q1 2024 and held it in 5 quarters. The position peaked at $1.3M in Q4 2025. 233 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- Verition Fund Management reported no remaining Nurix Therapeutics position as of Q3 2026 after selling out during the quarter.
- Verition Fund Management sold 30,405 Nurix Therapeutics shares in Q3 2026, an estimated $738K.
- Verition Fund Management first reported a position in Nurix Therapeutics in Q1 2024 and held it in 5 quarters.
- Verition Fund Management's Nurix Therapeutics position peaked at $1.3M in Q4 2025.
- 233 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.